This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2003 Oct 18;362(9392):1333; author reply 1334.

doi: 10.1016/S0140-6736(03)14601-6.

ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit

Keith Wheatley, Richard Gray

PMID: 14575997
DOI: 10.1016/S0140-6736(03)14601-6

Comment

ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit

Keith Wheatley et al. Lancet. 2003.

. 2003 Oct 18;362(9392):1333; author reply 1334.

doi: 10.1016/S0140-6736(03)14601-6.

Authors

Keith Wheatley, Richard Gray

PMID: 14575997
DOI: 10.1016/S0140-6736(03)14601-6

No abstract available

PubMed Disclaimer

Comment on

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
[No authors listed] [No authors listed] Lancet. 1992 Jan 4;339(8784):1-15. Lancet. 1992. PMID: 1345950 Review.
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON and AGO Collaborators. Parmar MK, et al. Lancet. 2003 Jun 21;361(9375):2099-106. doi: 10.1016/s0140-6736(03)13718-x. Lancet. 2003. PMID: 12826431 Clinical Trial.

Similar articles

ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit.
Newman G. Newman G. Lancet. 2003 Oct 18;362(9392):1333; author reply 1334. doi: 10.1016/S0140-6736(03)14602-8. Lancet. 2003. PMID: 14575996 No abstract available.
ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit.
Green JA. Green JA. Lancet. 2003 Oct 18;362(9392):1334; author reply 1334. doi: 10.1016/S0140-6736(03)14603-X. Lancet. 2003. PMID: 14575998 No abstract available.
Chemotherapy for ovarian cancer.
Cvitkovic E, Misset JL. Cvitkovic E, et al. N Engl J Med. 1996 May 9;334(19):1269; author reply 1270. N Engl J Med. 1996. PMID: 8606730 No abstract available.
Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer.
Muggia FM. Muggia FM. Semin Oncol. 2004 Dec;31(6 Suppl 15):19-24. doi: 10.1053/j.seminoncol.2004.11.024. Semin Oncol. 2004. PMID: 15726535 Review.
Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A. Colombo N, et al. Forum (Genova). 2000 Oct-Dec;10(4):323-32. Forum (Genova). 2000. PMID: 11535983 Review.

See all similar articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information